US pharmaceutical company Eli Lilly and Company has announced plans to invest more than $1 billion in India in the coming years to enhance manufacturing capabilities and bolster supply chains for its key medications. The company will collaborate with local contract manufacturers and establish a new Manufacturing and Quality center in Hyderabad to supervise production operations.
Recruitment for the Hyderabad facility is set to commence immediately, with job opportunities available for engineers, chemists, analytical scientists, and quality specialists. The hub is intended to support the company’s global manufacturing network and ensure a consistent availability of medications for various health conditions such as diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases.
Patrik Jonsson, the President of Lilly International, emphasized that this investment is part of the company’s strategy to expand its global production capacity. He stated, “We are committing substantial resources to enhance our manufacturing and supply capabilities worldwide. India will play a crucial role in facilitating our evolving product portfolio.”
This initiative follows the recent introduction of Lilly’s weight-loss and diabetes treatment, Mounjaro, in the Indian market, which has generated considerable international demand. Industry analysts anticipate that this investment will enable the company to secure a stable long-term supply amid growing competition in the obesity medication sector.
The announcement was met with enthusiasm by Telangana Chief Minister A. Revanth Reddy, who underscored Hyderabad’s increasing significance in the global healthcare landscape. Furthermore, Industries Minister Sridhar Babu highlighted the state’s emphasis on technology-driven progress and business-friendly environment, attracting multinational pharmaceutical companies.
Nivruti Rai, CEO of Invest India, affirmed that Lilly’s initiative underscores India’s position as a competitive pharmaceutical manufacturing hub. Since 2020, Lilly has allocated over $55 billion globally to expand production capacities, including in the United States, to meet the demand for new therapies. The investment in India represents another strategic step in this expansion plan, demonstrating the company’s commitment to integrating the country into its global supply chain network.